Ali Siam is Chief Business Officer (CBO) at Rubedo Life Sciences, a longevity biotech company based in Silicon Valley, where he leads business development and corporate strategy. The company has raised $60M from top tier investors from the US, EU, UK, MENA, and APAC, and announced a collaboration with Beiersdorf AG, parent company of Nivea, in 2024. Ali is from the MENA region, having been born in Kuwait to a Palestinian father and Kuwaiti mother, and was raised in the US in the suburbs of Boston. Prior to Rubedo, he was CBO at Celmatix, where he led the team to a €350M+ deal with Evotec SE and Bayer AG, and supported the development of their corporate and portfolio strategy.

Previously, he led corporate strategy, M&A advisory, portfolio strategy, and due diligence projects for public and private healthcare companies and institutional investors at management consulting firm LEK. He also led Healthtech and AI Drug Discovery collaborations in a BD team at AbbVie, in addition to developing go-to-market, launch, and lifecycle management strategy for large drug brands like Humira®. Ali also has strategic marketing and R&D experience from his time at Johnson & Johnson, is an inventor on an issued medtech patent, and holds an MBA from Boston College and a Bachelor of Science in Mechanical Engineering from Northeastern University.